Foreign enterprises divided more than 60% of the epilepsy drug market domestic drug enterprises need quality and technology go hand in hand

Epilepsy, commonly known as "sheep's horn wind" or "sheep's epileptic wind", is a chronic disease in which neurons suddenly discharge abnormally, leading to transient brain dysfunction. It is understood that in China approved the listing of about 18 kinds of anti-epileptic drugs, and Belgium UCC, Sanofi, Novartic, GlaxoSmithKline 4 foreign companies sales share accounted for 63.28 percent of the total anti-epileptic drug market.
data from more than 400 sample hospitals in 16 key cities show that the domestic market size of anti-epileptic drugs increased from 357 million yuan in 2011 to 668 million yuan in 2015, maintaining a double-digit growth rate every year, with sales of anti-epileptic drugs reaching about 670 million yuan in 2015.
in such a huge market lured by China's independent research and development of anti-epileptic drugs are also catching up. New anti-epileptic drugs, which were heavily marketed in 2014 and 2015: magnesium valproate, vanilla aldehyde, is independently developed by Chinese companies.
It is understood that the cost of taking domestic treatment of epilepsy drugs is only 80 to 100 yuan per month, the cost of taking imported epilepsy drugs in 500 to 1000 yuan, nearly 10 times the drug price gap, why epilepsy patients prefer imported drugs?
Du Hao, director of the Center for Neurosurgery at Wuhan General Hospital in Guangzhou Military Region, said, "There are many domestic and imported drugs for the treatment of epilepsy, and there is no great difference in the efficacy of controlling epilepsy, but by contrast, the side effects of imported drugs are smaller." Because some domestic drugs may cause dizziness, nausea and other side effects, patients will have physical discomfort, then patients will choose imported drugs. At the same time, due to the long clinical use of imported drugs, the continuous improvement of enterprises to make its blood, liver, nerve impact is smaller, relatively safe.
this shows that domestic enterprises want to share more part of the epilepsy drug market not only to improve the level of research and development, but also to improve the quality of drugs, reduce the occurrence of adverse reactions, will let patients believe in domestic drugs.
Because epilepsy itself is a very complex disease, even neurologist, if the research direction is not epilepsy, it is likely to make a less accurate judgment, according to the specific symptoms of patients can not choose the most appropriate and effective medication. There are many irregular hospitals for economic benefits, disorderly diagnosis and treatment, delay the patient's condition.
, Director Du Hao reminded that patients with initial epilepsy, the first treatment must go to the regular hospital neurology. (China Pharmaceutical News Network)